Biotricity Files FDA 510(k) For Expanded Use Of Its Biotres Cardiac Monitoring Device

  • Biotricity Inc BTCY has announced 510(k) submission to the FDA for a new form factor of its Biotres Cardiac Monitoring Device, a three-lead device for ECG and arrhythmia monitoring that is intended for lower-risk patients.
  • Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, commented, "We believe this variation of Biotres is an important step to having an expanded product portfolio with maximum variety for the $5B holter monitoring market."
  • Biotres offers the following feature set:
    • A wearable holter patch device that can provide continuous 3-channel recording of ECG (heart) data. All other known holter patch devices are 1 channel or 2 channels.
    • It can be worn continuously for 48 hours before needing to be charged for 1 hour.
    • Utilizes Bluetooth technology to offload data, reducing the time for diagnoses.
  • Price Action: BTCY shares are up 10.70% at $0.80 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!